Key result
High macrophage migration inhibitory factor (MIF) plasma levels significantly predicted the combined endpoint of all-cause death or hospitalization at 180 days (adjusted HR 2.35) in patients with HFpEF.
Why the study?
Do high plasma levels of macrophage migration inhibitory factor (MIF) predict all-cause death or hospitalization in patients with HFpEF?
Cohort (n=62)
No
Do high plasma levels of macrophage migration inhibitory factor (MIF) predict all-cause death or hospitalization in patients with HFpEF?
Hazard Ratio: 2.35 (95% CI 1.05–5.27)
p-value: p=0.0374
Elevated plasma levels of macrophage migration inhibitory factor (MIF) are associated with an increased risk of death or hospitalization and higher pulmonary pressures in patients with HFpEF.
High MIF levels were associated with worse HFpEF outcomes; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Prognostication in heart failure with preserved ejection fraction (HFpEF) is challenging and novel biomarkers are urgently needed. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays a crucial role in cardiovascular and various inflammatory diseases. Whether MIF is involved in HFpEF is unknown. METHODS AND RESULTS: Sixty-two patients with HFpEF were enrolled and followed up for 180 days. MIF plasma levels as well as natriuretic peptide (NP) levels were assessed. High MIF levels significantly predicted the combined end-point of all-cause death or hospitalization at 180 days in the univariate analysis (HR 2.41, 95% CI 1.12-5.19, p = 0.025) and after adjustment for relevant covariates in a Cox proportional hazard regression model (HR 2.35, 95% CI 1.05-5.27, p = 0.0374). Furthermore, MIF levels above the median were associated with higher pulmonary artery systolic pressure (PASP) as assessed by echocardiography (PASP 31 mmHg vs 48 mmHg in the low- and high-MIF group, respectively, p = 0.017). NPs significantly correlated with MIF in HFpEF patients (BNP p = 0.011; r = 0.32; NT-proBNP p = 0.027; r = 0.28). CONCLUSION: MIF was associated with clinical outcomes and might be involved in the pathophysiology of pulmonary hypertension in patients with HFpEF. These first data on MIF in HFpEF should stimulate further research to elucidate the role of this cytokine in heart failure. Trial registration NCT03232671.
No takes yet. Share an insight, caveat, or question.
Luedike et al. (2018) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=62). High macrophage migration inhibitory factor (MIF) plasma levels vs. Low MIF plasma levels was evaluated on Combined end-point of all-cause death or hospitalization at 180 days (HR 2.35, 95% CI 1.05-5.27, p=0.0374). High macrophage migration inhibitory factor (MIF) plasma levels significantly predicted the combined endpoint of all-cause death or hospitalization at 180 days (adjusted HR 2.35) in patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: